Jupiter Neurosciences, Inc. (JUNS)

Chart not available yet

Data will show when the stock starts trading.

Market Cap	148.95M
Revenue (ttm)	1.76M
Net Income (ttm)	-2.06M
Shares Out	33.10M
EPS (ttm)	-0.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About JUNS

Jupiter Neurosciences is a clinical stage research and development pharmaceutical company. The Company has developed a unique resveratrol platform product targeting treatment of neuro-inflammation. The product, called JOTROL™, has many potential indications of use for rare diseases, which of we primarily are targeting Mucopolysaccharidoses Type 1, Friedreich’s Ataxia, and MELAS as well as ALS which is in an early development stage. In the larger disease areas, we are primarily targeting Mild Cognitive Impairment/early Alzheimer’s disease with T...

• Industry: Pharmaceuticals
• Sector: Healthcare
• Founded: 2015
• Employees: 5
• Stock Exchange: NASDAQ
• Ticker Symbol: JUNS
• Website: https://jupiterneurosciences.com/